Security Snapshot

UTAH MEDICAL PRODUCTS INC - Common Shares (UTMD) Institutional Ownership

CUSIP: 917488108

13F Institutional Holders and Ownership History from Q1 2014 to Q3 2026

13F reference period

Q2 2026

Institutions Reporting

114

Shares (Excl. Options)

2.32MFull value: 2,317,789 · shares · 30 Jun 2026

Price

$68.98

The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period
Security type / class
Equity / Common Shares
Symbol
UTMD on Nasdaq
All holders as of 30 Jun 2026
Q2 2026
Total 13F shares
2,317,789
Latest holder snapshot 5 signals
Total 13F value
$159,890,126
Portfolio coverage rank
0%
Share change
+52,689
Value change
+$3,823,891
Number of holders
114
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
3,188,980
SEC-reported price per share
$74.05
Insider filing price
$74.05
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • UTMD - UTAH MEDICAL PRODUCTS INC - Common Shares is tracked under CUSIP 917488108.
  • 114 institutions reported positions in Q2 2026.
  • 5 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 119 to 114 between Q1 2026 and Q2 2026.
  • SEC-reported value moved from
    $140.49MFull value: $140,491,697 · USD · 31 Mar 2026
    to
    $159.89MFull value: $159,890,126 · USD · 30 Jun 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 114 institutions filings for Q2 2026.

Open SEC evidence

Security key

917488108

13F reference period

Q2 2026

13F holders

114

13D/G owners

5

CIK / CUSIP context first

Open Q2 2026 holders UTMD full holder history UTAH MEDICAL PRODUCTS INC SEC filings UTAH MEDICAL PRODUCTS INC company facts UTAH MEDICAL PRODUCTS INC insider transactions

Broader feeds

Latest 13F filings Latest 13D/G filings All securities

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
5
Security
UTMD
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BRANDES INVESTMENT PARTNERS, LP 15% +5.7% $33,560,410 +$1,799,511 475,158 +5.7% BRANDES INVESTMENT PARTNERS, LP 30 Jun 2026
DIMENSIONAL FUND ADVISORS LP 6.1% $11,239,863 197,466 Dimensional Fund Advisors LP 30 Jun 2025
RENAISSANCE TECHNOLOGIES LLC 5.5% -17% $12,417,743 -$3,870,524 175,814 -24% Renaissance Technologies LLC 30 Jun 2026
BlackRock, Inc. 5.3% +6.6% $9,829,260 +$231,666 172,684 +2.4% BlackRock, Inc. 30 Jun 2025
FMR LLC 2.7% $4,848,900 92,360 FMR LLC 31 Dec 2024
As of 30 Jun 2026, 114 institutional investors reported holding
2.32MFull value: 2,317,789 · shares · 30 Jun 2026
shares of UTAH MEDICAL PRODUCTS INC - Common Shares (UTMD). This represents 73% of the company’s total
3.19MFull value: 3,188,980 · shares · Stored outstanding share count
outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
64%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BRANDES INVESTMENT PARTNERS, LP 15% 475,158 +5.8% 0.23% $32,776,399
BlackRock, Inc. 6.4% 203,690 +8.5% 0% $14,050,520
DIMENSIONAL FUND ADVISORS LP 6.2% 198,817 +0.46% 0% $13,715,681
RENAISSANCE TECHNOLOGIES LLC 5.5% 175,814 -4.5% 0.02% $12,127,650
VANGUARD CAPITAL MANAGEMENT LLC 4.2% 134,535 -2.9% 0% $9,280,224
GEODE CAPITAL MANAGEMENT, LLC 3.4% 108,048 -10% 0% $7,454,824
Minerva Advisors LLC 2.9% 93,615 0% 4.1% $6,457,563
HOTCHKIS & WILEY CAPITAL MANAGEMENT LLC 2.7% 85,231 -4.4% 0.02% $5,879,234
RICE HALL JAMES & ASSOCIATES, LLC 2.2% 71,363 +5.1% 0.24% $4,922,620
MORGAN STANLEY 2.2% 69,670 +43% 0% $4,805,903
STATE STREET CORP 2% 63,937 -0.72% 0% $4,429,595
Quantinno Capital Management LP 1.4% 43,074 +44% 0% $2,971,274
UBS Group AG 1.1% 34,369 -6.9% 0% $2,370,773
Bank of New York Mellon Corp 1.1% 34,263 +6.8% 0% $2,363,453
NORTHERN TRUST CORP 0.94% 30,104 -0.62% 0% $2,076,574
Huber Capital Management LLC 0.91% 29,009 -19% 0.29% $2,001,041
Cardinal Capital Management 0.85% 27,094 +2.1% 0.23% $1,877,213
EVERETT HARRIS & CO /CA/ 0.75% 23,933 -6.4% 0.02% $1,650,898
PRICE T ROWE ASSOCIATES INC /MD/ 0.69% 21,938 +20% 0% $1,515,000
O'SHAUGHNESSY ASSET MANAGEMENT, LLC 0.68% 21,683 +1.9% 0.01% $1,495,693
SEGALL BRYANT & HAMILL, LLC 0.68% 21,547 0% 0.02% $1,486,312
VANGUARD PORTFOLIO MANAGEMENT LLC 0.64% 20,276 +16% 0% $1,398,638
VANGUARD FIDUCIARY TRUST CO 0.63% 20,014 +5% 0% $1,380,566
BARD ASSOCIATES INC 0.58% 18,455 +0.51% 0.28% $1,278,670
FMR LLC 0.57% 18,068 +0.03% 0% $1,246,297

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
51
Headline period
Q2 2026
Rows shown
1-25 of 51
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 41,910 $3,111,735 +$378,400 $74.05 18
2026 Q2 2,317,789 $159,890,126 +$3,823,891 $68.98 114
2026 Q1 2,266,199 $140,491,697 +$10,514,177 $61.99 119
2025 Q4 2,099,545 $117,525,511 -$3,861,909 $55.96 117
2025 Q3 2,166,272 $136,441,085 +$654,850 $62.97 115
2025 Q2 2,154,610 $122,645,130 -$4,286,491 $56.92 109
2025 Q1 2,232,321 $125,139,291 -$4,053,654 $56.04 107
2024 Q4 2,305,146 $141,733,881 -$6,984,040 $61.47 112
2024 Q3 2,408,468 $161,160,273 +$1,503,694 $66.91 109
2024 Q2 2,402,050 $160,517,663 -$6,987,298 $66.81 99
2024 Q1 2,489,842 $177,079,892 -$5,994,623 $71.11 99
2023 Q4 2,515,087 $211,858,896 -$5,241,769 $84.22 88
2023 Q3 2,572,783 $221,288,021 +$1,886,299 $86.00 91
2023 Q2 2,546,722 $237,462,990 +$487,123 $93.20 89
2023 Q1 2,542,875 $241,013,763 +$8,482,645 $94.77 86
2022 Q4 2,546,245 $255,980,665 +$1,190,438 $100.53 81
2022 Q3 2,535,532 $216,324,656 -$31,278,340 $85.31 75
2022 Q2 2,559,522 $219,885,103 -$450,030 $85.90 74
2022 Q1 2,572,731 $231,180,696 -$2,805,351 $89.86 84
2021 Q4 2,603,370 $260,419,500 -$912,880 $100.00 78
2021 Q3 2,601,860 $241,516,691 +$243,574 $92.83 72
2021 Q2 2,599,575 $221,087,106 -$2,811,784 $85.04 68
2021 Q1 2,632,036 $227,952,680 +$1,009,922 $86.60 78
2020 Q4 2,620,725 $220,943,842 -$2,326,872 $84.30 76
2020 Q3 2,651,007 $211,813,071 -$2,768,168 $79.87 83
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .